Skip to main content

Private equity

Sofinnova Partners closed its Crossover II fund at €725 million, above target, to back Late-Stage European Life Sciences companies

Monday, November 16, 2026 · first reported by HedgeCo and 1 other

Sofinnova Partners closed Sofinnova Crossover II at €725 million ($815 million), above its original target. The fund will back about 15 late-stage European life sciences companies, with roughly 80% allocated to Europe.

Fund
Sofinnova Crossover II
Size
€725M (≈$815M)
Stage
Final close
Asset class
Private equity, Venture
Geography
Europe

In the data This close in the fund closes table · Every Sofinnova Partners close

The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.

See an error?

Coverage

2 sources

Got news? Send it to us →